Publication:
Arterial and Venous Involvement in Behçet’s Disease

dc.contributor.authorsAlibaz-Oner F., Direskeneli H.
dc.date.accessioned2022-03-15T02:17:02Z
dc.date.accessioned2026-01-11T08:07:15Z
dc.date.available2022-03-15T02:17:02Z
dc.date.issued2021
dc.description.abstractBehçet’s disease (BD) is a chronic, multisystemic, inflammatory disease characterized by recurrent attacks of mucocutaneous, ocular, musculoskeletal, vascular, central nervous system and gastrointestinal manifestations. Vascular involvement is observed in up to 40% of the patients with BD, especially in young males and is one of the major causes of mortality and morbidity. Both venous and arterial disease is observed. Glucocorticoids, azathioprine and cyclophosphamide are recommended as the first-line treatments in vascular BD (VBD). But increasing data with TNF inhibitors and interferons suggest that these agents may also be acceptable options for the management of refractory cases. Anticoagulant usage is still controversial with limited data coming from retrospective studies. There is a clear need for randomized, controlled studies for the management of VBD. © 2021, Springer Nature Switzerland AG.
dc.identifier.doi10.1007/978-3-030-67175-4_20
dc.identifier.issn22826505
dc.identifier.urihttps://hdl.handle.net/11424/248275
dc.language.isoeng
dc.publisherSpringer Nature
dc.relation.ispartofRare Diseases of the Immune System
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAneursyms
dc.subjectArterial thrombosis
dc.subjectVenous thrombosis
dc.titleArterial and Venous Involvement in Behçet’s Disease
dc.typebookPart
dspace.entity.typePublication
oaire.citation.endPage275
oaire.citation.startPage257
oaire.citation.titleRare Diseases of the Immune System

Files